Actively Recruiting
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Led by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Updated on 2026-02-25
500
Participants Needed
1
Research Sites
126 weeks
Total Duration
On this page
Sponsors
S
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Lead Sponsor
S
Shanghai Pulmonary Hospital, Shanghai, China
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this observational study is to evaluate the safety and efficacy of adebrelimab in the perioperative and advanced-stage treatment of small cell lung cancer （SCLC） under real-world conditions. The main questions it aims to answer are: 1. The safety of adebrelimab treatment in patients with advanced SCLC under real-world conditions, with a specific focus on the incidence of grade ≥3 immune-related adverse events. Safety monitoring begins when patients start receiving adebrelimab treatment and continues until 90 days after the last dose of adebrelimab. 2. Observe and evaluate the efficacy of adebrelimab in patients with small cell lung cancer under real-world conditions. This includes overall survival (OS), progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). Additionally, the study seeks to further explore the impact of patient baseline characteristics, such as brain metastases or liver metastases, and biomarkers on prognosis.
CONDITIONS
Official Title
A Real-World Study Evaluating the Efficacy and Safety of Adebrelimab in Patients With Advanced SCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically or cytologically confirmed extensive-stage small cell lung cancer
- Age 18 years or older
- Investigator determines patient is eligible for or is already receiving adebrelimab treatment
You will not qualify if you...
- Currently receiving other immune-modulating drugs or therapies
- Participating in other interventional studies
- Having other concurrent malignancies
- Missing key study-related data
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Shanghai General Hospital
Shanghai, China, 201620
Actively Recruiting
Research Team
Q
Qingnan Zhao, PhD
CONTACT
Q
Qian Xue, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here